Purification of Human Pituitary Prolactin For many years it has been known that growth hormone and prolactin from several mammalian species are separate and distinct protein molecules (Lyons & Dixon 1966) . However, human growth hormone (HGH) contains intrinsic prolactin activity which cannot be removed by purification procedures, and so attempts to isolate prolactin by bioassay of human pituitary fractions have resulted in purification of HGH (Lyons et al. 1960 ).
It was not until Friesen and his colleagues developed an immunological method which could distinguish between human prolactin and human growth hormone that it became possible to purify human prolactin ). The method utilized antiserum to sheep prolactin which crossreacted with human prolactin but not with human growth hormone. The human pituitary prolactin isolated by Friesen differed both immunologically and chemically from human growth hormone and possessed a prolactin activity of 30 iu/mg . Isolation of human prolactin with similar properties has also been reported by Lewis et al. (1972) . The amino acid at the N-terminus of the human prolactin molecule is leucine (Niall 1972 , Lewis et al. 1972 , but HGH has phenylalanine in this position (Li et al. 1966) .
Isolation of human prolactin from pituitaries is difficult because of the low content of this hormone in the glands compared with growth hormone (Guyda et al. 1971) , and also because of the high prolactin activity which is intrinsic in human growth hormone. Moreover, enzymatic degradation of HGH can result in enhancement of its prolactin activity (Lewis et al. 1972) .
A high concentration of immunoreactive prolactin has been reported in human amniotic fluid , but this hormone has not yet been isolated and characterized chemically. It is immunologically related to human pituitary prolactin, but is not necessarily identical in chemical structure.
Dr Isabel A Forsyth (National Institutefor Research in Dairying, Shinfield, Reading) Bioassay of Prolactin The development of bioassay methods which are sufficiently sensitive to measure prolactin levels in human plasma has played an important part in the study of this hormone in man , Frantz et al. 1972 ). The methods all depend on the ability of prolactin to stimulate biochemical activity and 'milk' secretion by lobulo-alveolar mammary tissue in vitro. Endpoints used include histological assessment of the amount of secretion accumulating in the alveolar lumina in mid-pregnant mouse (Kleinberg & Frantz 1971) or pseudopregnant rabbit mammary gland (Forsyth & Myres 1971 ) and measurement of the incorporation Of 32p into casein by mouse mammary gland (Turkington 1971). Plasma to be assayed can be added directly to the culture medium without prior extraction and only about 2-3 ml plasma is required for an assay. In general, very good agreement has been reported between the results of bioassay and radioimmunoassay measurements on individual plasma samples (Besser et al. 1972 , Frantz et al. 1972 ). By contrast, the local pigeon crop assay appears to give considerable overestimates of plasma prolactin levels and although it is still useful for the assay of purified hormone preparations, it cannot be regarded as suitable for the assay of plasma. Even in vitro mammary gland bioassays have a number of disadvantages. Their sample capacity is small, the methods are time-consuming, basal levels cannot usually be measured and responses may occur to two other human hormones with lactogenic activity, growth hormone and placental lactogen, although the use of appropriate antisera removes such interference. Despite this, they have enabled many useful clinical measurements to be made and do not require supplies of the still scarce human prolactin, as sheep prolactin is suitable as a standard. Further, it is important to be able to measure biological as well as immunological activity, at least in selected samples. For the future, it is hoped that radioligand assays, using prolactin receptor sites on plasma membranes (Turkington & Frantz 1972) will combine the advantages of bioassay and radioimmunoassay methods. 
Radioimmunoassay of Human Prolactin
Only recently have immunological and other techniques demonstrated that prolactin is a separate entity from human growth hormone (HGH). For a routine radioimmunoassay three requirements must be met: first, an adequate supply of purified antigen for standard, labelling and immunization; secondly, a supply of specific antisera; and thirdly, a method for the separation of antibody-bound and free hormone. At present, the major problem with the radioimmunoassay of human prolactin is that the purified hormone is only available in very limited quantities. A num-ber of workers have partly overcome this by the use of assays based on prolactin from other species which may show a partial cross-reaction with human material (Bryant et al. 1971 , Guyda & Friesen 1971 , Jacobs et al. 1971 , L'Hermite et al. 1972 ). These assays are suitable for qualitative and in some cases quantitative estimations of circulating hormones. Only one truly homologous radioimmunoassay using purified prolactin for standard, labelling and immunization has been published .
The studies in our laboratory have been directed towards the establishment of a homologous radioimmunoassay for human prolactin designed for routine clinical use. Purified human prolactin was kindly supplied by Dr H Friesen and used for labelling and standard. Another preparation, described by Mr Davies & Dr Hartree (see p 862) was used for immunization. Antibodybound and free hormone were separated using a second antibody system. Labelled hormone (125L-human prolactin) was prepared by a modification of the chloramine-T method of Greenwood et al. (1963) . Various antisera were screened for use in the assay, including 22 to sheep prolactin, 11 to HPL and 18 to Raben HGH. All could bind labelled hormone but the resulting assays were not sufficiently sensitive to measure basal circulating levels of prolactin.
However, using an antiserum to the prolactin prepared by Mr Davies, a specific and sensitive radioimmunoassay for prolactin has been developed. In this system, HGH has only 0.01 % of the activity of prolactin, and other hormones tested show no cross-reaction. The minimum detectable level of prolactin in serum is 0.5 ng/ml and the assay has been applied to the measurement of prolactin in various physiological and clinical situations.
In normal females throughout the menstrual cycle levels varied between 6 and 50 ng/ml serum; no consistent pattern of release could be observed. The normal range in adult males was 6-25 ng/ml serum. During pregnancy there is a rise in circulating levels of prolactin in maternal serum (20-340 ng/ml) and high levels of prolactin (0.3-8 ,ug/ml) can be found in amniotic fluid. Prolactin release has been shown to occur after both suckling and injection of thyrotrophin-releasing hormone, with an increase of between two and twenty-fold over basal levels. In a series of 22 patients with galactorrhcea, serum levels varied between 35 and 1150 ng/ml; in no case was there a significant elevation of HGH levels. In 5 of these cases the levels fell during treatment with 2-Br-a-ergocryptine (CB 154) from 260-1000 to 8-40 ng/ml. These results confirm that human prolactin can be measured independently of HGH. The present method is sufficiently sensitive to measure levels
